Literature DB >> 12072497

Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence.

Andreas Jekle1, Birgit Schramm, Prerana Jayakumar, Verena Trautner, Dominique Schols, Erik De Clercq, John Mills, Suzanne M Crowe, Mark A Goldsmith.   

Abstract

The Sydney Blood Bank Cohort is a group of patients with slowly progressive infection by a human immunodeficiency virus strain containing spontaneous deletions within the nef long terminal repeat region. In 1999, 18 years after the initial infection, one of the members (D36) developed AIDS. In this work, we used an ex vivo human lymphoid cell culture system to analyze two viral isolates obtained from this patient, one prior to the onset of AIDS in 1995 and one after disease progression in 1999. Both D36 isolates were less potent in depleting CD4(+) T cells than a reference dualtropic, nef-bearing viral isolate. However, the 1999 isolate was measurably more cytotoxic to CD4(+) T cells than the 1995 isolate. Interestingly, although both isolates were nearly equally potent in depleting CCR5(+) CD4(+) T cells, the cytotoxic effect of the 1999 isolate toward CCR5(-) CD4(+) T cells was significantly higher. Furthermore, GHOST cell infection assays and blocking experiments with the CXCR4 inhibitor AMD3100 showed that the later D36 1999 isolate could infect both CCR5(+) and CCR5(-) CXCR4(+) cells efficiently, while infection by the 1995 isolate was nearly completely restricted to CCR5(+) cells. Sequence analysis of the V1/V2 and V3 regions of the viral envelope protein gp120 revealed that the more efficient CXCR4 usage of the later isolate might be caused by an additional potential N-glycosylation site in the V1/V2 loop. In conclusion, these data show that an in vivo evolution of the tropism of this nef-deleted strain toward an X4 phenotype was associated with a higher cytopathic potential and progression to AIDS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072497      PMCID: PMC136331          DOI: 10.1128/jvi.76.14.6966-6973.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

Review 1.  Mitochondria and cell death. Mechanistic aspects and methodological issues.

Authors:  P Bernardi; L Scorrano; R Colonna; V Petronilli; F Di Lisa
Journal:  Eur J Biochem       Date:  1999-09

2.  Mechanism for down-regulation of CD28 by Nef.

Authors:  T Swigut; N Shohdy; J Skowronski
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

Review 3.  New insights into host factors in HIV-1 pathogenesis.

Authors:  S Rowland-Jones; S Pinheiro; R Kaul
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

Review 4.  HIV with multiple gene deletions as a live attenuated vaccine for AIDS.

Authors:  R C Desrosiers
Journal:  AIDS Res Hum Retroviruses       Date:  1992-03       Impact factor: 2.205

5.  HIV type 1 nef gene inhibits tumor necrosis factor alpha-induced apoptosis and promotes cell proliferation through the action of MAPK and JNK in human glial cells.

Authors:  G A Robichaud; L Poulin
Journal:  AIDS Res Hum Retroviruses       Date:  2000-12-10       Impact factor: 2.205

6.  Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism.

Authors:  K Kato; H Sato; Y Takebe
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

7.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule.

Authors:  R A Fouchier; M Groenink; N A Kootstra; M Tersmette; H G Huisman; F Miedema; H Schuitemaker
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

8.  Stable expression of human immunodeficiency virus type 1 Nef confers resistance against Fas-mediated apoptosis.

Authors:  K Yoon; J G Jeong; S Kim
Journal:  AIDS Res Hum Retroviruses       Date:  2001-01-20       Impact factor: 2.205

Review 9.  Host factors and the pathogenesis of HIV-induced disease.

Authors:  A S Fauci
Journal:  Nature       Date:  1996-12-12       Impact factor: 49.962

10.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

View more
  13 in total

1.  R5 human immunodeficiency virus type 1 (HIV-1) replicates more efficiently in primary CD4+ T-cell cultures than X4 HIV-1.

Authors:  Becky Schweighardt; Ann-Marie Roy; Duncan A Meiklejohn; Edward J Grace; Walter J Moretto; Jonas J Heymann; Douglas F Nixon
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

2.  Nef alleles from human immunodeficiency virus type 1-infected long-term-nonprogressor hemophiliacs with or without late disease progression are defective in enhancing virus replication and CD4 down-regulation.

Authors:  Andrea Crotti; Francesca Neri; Davide Corti; Silvia Ghezzi; Silvia Heltai; Andreas Baur; Guido Poli; Elena Santagostino; Elisa Vicenzi
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

3.  Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source.

Authors:  Melissa J Churchill; David I Rhodes; Jennifer C Learmont; John S Sullivan; Steven L Wesselingh; Ian R C Cooke; Nicholas J Deacon; Paul R Gorry
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  Tissue-resident macrophages are productively infected ex vivo by primary X4 isolates of human immunodeficiency virus type 1.

Authors:  Prerana Jayakumar; Irina Berger; Frank Autschbach; Mark Weinstein; Benjamin Funke; Eric Verdin; Mark A Goldsmith; Oliver T Keppler
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells.

Authors:  Andreas Jekle; Oliver T Keppler; Erik De Clercq; Dominique Schols; Mark Weinstein; Mark A Goldsmith
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

6.  Biological signature characteristics of primary isolates from human immunodeficiency virus type 1 group O in ex vivo human tonsil histocultures.

Authors:  Silvia Geuenich; Lars Kaderali; Ina Allespach; Serkan Sertel; Oliver T Keppler
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

7.  Determinants in HIV-1 Nef for enhancement of virus replication and depletion of CD4+ T lymphocytes in human lymphoid tissue ex vivo.

Authors:  Stefanie Homann; Nadine Tibroni; Ingo Baumann; Serkan Sertel; Oliver T Keppler; Oliver T Fackler
Journal:  Retrovirology       Date:  2009-01-15       Impact factor: 4.602

8.  Phenotype and envelope gene diversity of nef-deleted HIV-1 isolated from long-term survivors infected from a single source.

Authors:  Lachlan Gray; Melissa J Churchill; Jasminka Sterjovski; Kristie Witlox; Jennifer C Learmont; John S Sullivan; Steven L Wesselingh; Dana Gabuzda; Anthony L Cunningham; Dale A McPhee; Paul R Gorry
Journal:  Virol J       Date:  2007-07-16       Impact factor: 4.099

9.  Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo.

Authors:  Paul R Gorry; Dale A McPhee; Erin Verity; Wayne B Dyer; Steven L Wesselingh; Jennifer Learmont; John S Sullivan; Michael Roche; John J Zaunders; Dana Gabuzda; Suzanne M Crowe; John Mills; Sharon R Lewin; Bruce J Brew; Anthony L Cunningham; Melissa J Churchill
Journal:  Retrovirology       Date:  2007-09-23       Impact factor: 4.602

10.  Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists.

Authors:  Katrien Princen; Sigrid Hatse; Kurt Vermeire; Erik De Clercq; Dominique Schols
Journal:  Retrovirology       Date:  2004-03-08       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.